July 2025 - BioMedWire (BMW)

ThursdayJul 31, 2025 10:00 am

New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease

Computer scientists have designed an AI-based speech screening tool that could help people ascertain whether they could be exhibiting signs of Parkinson’s. The research explaining this speech tool appeared in the npj Parkinson’s Disease journal. According to the researchers, all that a person has to do is to say aloud two short sentences that contain every single letter of the alphabet, 26 letters in total. Such sentences are referred to as pangrams, and the web-based tool utilizes two such sentences. In just a matter of seconds, the AI tool is able to analyze the way in which someone has spoken…

TuesdayJul 29, 2025 1:45 pm

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology developed at UC Davis. The company has secured regulatory alignment with the FDA and is preparing for a pivotal U.S. clinical trial. IzoView offers a proprietary, patient-centric alternative to mammography for dense breast tissue imaging. A comprehensive business and financial plan supports execution across clinical, regulatory, and commercial milestones. Awareness campaigns, including breastct.com and a company podcast, are primed to drive engagement and investor visibility. Izotropic (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of…

TuesdayJul 29, 2025 10:00 am

Study Discovers That Autoantibodies in Patients Could Boost Cancer Immunotherapy

For years, oncologists have been baffled by why checkpoint inhibitors work for some cancer patients and not others. This challenge has made it difficult for these immunotherapies to be widely used since it isn’t easy to predict who will benefit and yet the treatments are currently very expensive. Now a new study whose findings appeared in the journal Nature has found that autoantibodies, the proteins known to drive autoimmune diseases like rheumatoid arthritis and lupus, could be the missing link that helps checkpoint inhibitors to be more effective against different kinds of cancer and other diseases. Doctor Aaron Ring, the…

MondayJul 28, 2025 9:00 am

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis) drug CNM-Au8® in 2026, a market that is expected to reach $1.3 billion by 2034 with significant unmet need. Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months of 2025 could be major valuation catalysts for investors. Biomarker and survival data from over 150 patients will be critical to the company’s regulatory case and expects important NfL data in the fourth quarter of 2025. Clene is preparing to initiate a confirmatory Phase 3 ALS trial…

FridayJul 25, 2025 10:00 am

Survey Finds That US Healthcare Workers Worry About Personal Safety

According to a new survey, approximately 60% of workers in the U.S. healthcare sector are concerned about their personal safety while at work and these concerns are prompting many to consider quitting their positions. This situation is concerning because the healthcare industry is already facing worker shortages and those who want to leave could worsen matters. The survey found that about 21% (3 million individuals) of healthcare workers in the United States say they worry about facing verbal harassment by patients most times or each time they go to their workplaces. Reports of aggressive incidents were widespread among survey participants.…

ThursdayJul 24, 2025 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results

Severe oral mucositis (“SOM”) often necessitates hospitalization, opioid pain management and feeding tube placement, substantially lowering quality of life. Soligenix has taken on this challenge with SGX942, a treatment aimed at reducing tissue inflammation, promoting healing and supporting immune response. The company is in the process of analyzing combined phase 2 and 3 datasets to design a second phase 3 study. Oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment, continues to wreak havoc on patients undergoing cancer care, prompting an urgent need for effective interventions. Soligenix (NASDAQ: SNGX) is stepping forward with SGX942, a novel therapeutic aimed…

ThursdayJul 24, 2025 10:00 am

Global Vaccination Goals at Risk as 14 Million Kids Miss Crucial Shots

Latest UN data indicates that at least 14 million kids didn’t receive life-saving shots of vaccines against tetanus, whooping cough and diphtheria in 2024. This threatens the attainment of global vaccination goals. The data shows that over two-thirds of children categorized as “zero-dose” kids (those who didn’t receive a single dose of the needed vaccinations) were in low-income and middle-income countries around the world. In 2024, approximately 115 million kids got at least a dose of the DTP vaccine against diphtheria, pertussis and tetanus. This accounted for 89% of all infants around the world. 85% of the kids who got…

TuesdayJul 22, 2025 10:00 am

Unexpected Finding Potentially Opens the Door to Universal Vaccines Against Cancer

A team of researchers testing an experimental messenger RNA (mRNA) vaccine managed to ramp up the ability of immunotherapy to combat tumors in a study using mouse models. This finding potentially brings scientists one step closer to developing universal vaccines that can supercharge the immune system in its fight against cancer. The team, based at University of Florida, found that using the test vaccine together with immune checkpoint inhibitors had the effect of strengthening the immune system’s ability to reduce or even eliminate tumors in the mice. What the researchers found surprising was that the anticancer effect was triggered even…

FridayJul 18, 2025 10:00 am

Individuals Who Develop Multiple Sclerosis Have More Doctor Visits Decades Before Their Diagnosis

A new study has found that individuals who are later diagnosed with multiple sclerosis (MS) tend to visit their doctor more, are admitted to hospitals more, and visit emergency rooms more frequently decades before they are eventually diagnosed with MS in comparison to those who don’t develop the condition. This often happens more than 20 years before an MS diagnosis is made. These findings were made by researchers in Canada who used healthcare data from Ontario, the country’s province with the largest population. The study was funded by MS Canada and the National MS Society. The team conducted a retrospective…

FridayJul 18, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial

Recent data indicates Soligenix’s HyBryte(TM) is showing promising treatment success in early-stage cutaneous T-cell lymphoma. “With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,” leading investigator states. No new FDA-approved, skin-directed therapies have been introduced in more than a decade, and conventional options carry risks. Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study and…